ClinicalTrials.gg
CompletedNCT01585766Updated Oct 29, 2018Results posted

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

A Phase 1 interventional study of MEDI-551 30 MG-IV and MEDI-551 60 MG-SC in Multiple Sclerosis, Relapsing Forms, sponsored by MedImmune LLC. Completed at 16 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-10-29.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.

Enrollment
404th of 879
56 · median 50
Started
2012
with 40 others
Phase 1
105 of 1,192
18 open now
Registered
306th of 1,192
by date

Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 404th largest by enrollment of the 879 interventional ones that give a count, is one of 41 that started in 2012, is one of 105 in phase 1, and was the 306th registered.

Multiple Sclerosis

3,269 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:

179 more — sign in →

All 184 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,192 studies in Multiple Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of ascending intravenous (IV) and subcutaneous (SC) doses of MEDI-551 in adult subjects with relapsing forms of multiple sclerosis (MS).

Read the detailed description

This is a Phase 1, multicenter, multinational, randomized, blinded, placebo-controlled, dose-escalation study to evaluate the safety and tolerability of IV and SC doses of MEDI-551 in adult subjects with relapsing forms of MS.

03

Conditions studied

  • Multiple Sclerosis, Relapsing Forms

Keywords

  • MAb, B cell, depletion, RMS
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed relapsing form of MS (ie, RRMS, SPMS, PRMS, or CIS) according to revised 2010 McDonald criteria and MRI brain lesions consistent with MS on screening
  • At least 1 documented relapse within the past 3 years prior to screening
  • EDSS between 0.0 and 6.5 at screening
  • Have no more than 20 Gd-enhancing T1 brain lesions detected by cranial MRI scan

Exclusion criteria

Exclusion Criteria:

  • Subjects with impaired renal function
  • Major surgery within 8 weeks of the screening visit
  • Subjects who are unable to undergo cranial MRI scan
  • A history of to Gd-containing MRI contrast agents
  • Has received within 1 year prior to screening: monoclonal antibodies, experimental B-cell depleting agents, or treatment with natalizumab (Tysabri) for greater than 3 months
  • Receiving monthly methylprednisone or equivalent for disease modification of a relapsing form of MS
  • Known sensitivity to acetaminophen/paracetamol, diphenhydramine or equivalent antihistamine, methylprednisolone or equivalent glucocorticoid, or to any component of the drug
  • Diagnosis of PPMS, neuromyelitis optica, or other non-MS variant of neuro-inflammatory or demyelinating diseases
  • Any history of opportunistic infection or the presence of active infection within two months prior to screening or any herpes zoster infection that has not resolved within 12 weeks prior to screening
  • Any findings during the screening phase, including physical, neurological, laboratory, or examination as per protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    MEDI-551 30 MG-IV

    Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.

    Drug: MEDI-551 30 MG-IV

  • Experimental
    MEDI-551 60 MG-SC

    Participants received SC injection of 60 mg MEDI-551 on Day 1.

    Drug: MEDI-551 60 MG-SC

  • Experimental
    MEDI-551 100 MG-IV

    Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.

    Drug: MEDI-551 100 MG-IV

  • Experimental
    MEDI-551 300 MG-SC

    Participants received SC injection of 300 mg MEDI-551 on Day 1.

    Drug: MEDI-551 300 MG-SC

  • Experimental
    MEDI-551 600 MG-IV

    Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.

    Drug: MEDI-551 600 MG-IV

  • Placebo comparator
    PLACEBO-IV-SC

    Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1.

    Drug: PLACEBO-IV-SC

Interventions

  • Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.

  • Participants received SC injection of 60 mg MEDI-551 on Day 1.

  • DrugPLACEBO-IV-SC

    Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1

  • Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.

  • Participants received SC injection of 300 mg MEDI-551 on Day 1.

  • Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A TEAE were the events between administration of study drug (Day 1) and Day 169 that were absent before treatment or that worsened relative to pre-treatment state. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0

    Time frame: From study drug administration (Day 1) through the end of treatment period (Day 169)

  2. Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

    A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect in the offspring of a participant who received the study drug. The TESAEs were the events between administration of study drug (Day 1) and long term follow up period (up to 18 months after early discontinuation visit or 24-week treatment period) that were absent before treatment or that worsened relative to pre-treatment state. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0

    Time frame: From study drug administration (Day 1) through the long term follow up period (up to 18 months after early discontinuation visit or 24 week treatment period).

  3. Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs

    Any clinically significant change in laboratory evaluations were recorded as AEs. The following parameters were analyzed for laboratory evaluations: haematology, serum chemistry, and urinalysis. Number of participants with TEAEs related to laboratory evaluations were reported.

    Time frame: From study drug administration (Day 1) through the end of treatment period (Day 169)

  4. Number of Participants With Vital Sign Abnormalities Reported as TEAEs

    Vital sign parameters included blood pressure, temperature, pulse rate, and respiratory rate. The number of participants with TEAEs related to vital signs in participants were reported.

    Time frame: From study drug administration (Day 1) through the end of treatment period (Day 169)

Secondary outcomes

  1. Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI-551

    The time to reach the maximum observed serum concentration of MEDI-551.

    Time frame: Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169

  2. Maximum Observed Serum Concentration (Cmax) of MEDI-551

    The maximum observed serum concentration (Cmax) of MEDI-551.

    Time frame: Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169

  3. Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC 0-last) of MEDI-551

    The area under the concentration time curve from time 0 (dosing time) to the last measurable concentration (AUC 0-last) of MEDI-551.

    Time frame: Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169

  4. Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity) of MEDI-551

    The area under the concentration-time curve from dosing extrapolated to infinity (AUC 0-infinity) of MEDI-551.

    Time frame: Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169

  5. Dose Normalized Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity/D) of MEDI-551

    The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity post dose normalized by MEDI-551.

    Time frame: Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169

  6. Clearance of MEDI-551

    Systemic clearance (CL) for MEDI-551 IV cohorts and apparent clearance (CL/F) for MEDI-551 SC cohorts were calculated

    Time frame: Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169

  7. Terminal Elimination Half-life (t1/2) of MEDI-551

    The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI-551.

    Time frame: Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169

  8. Absolute Subcutaneous Bioavailability (F%) of MEDI-551

    Bioavailability (F%) is the fraction of the study drug absorbed through non-intravenous administration compared with the corresponding intravenous administration of the same drug.

    Time frame: Predose (Day 1) and Days 4, 8, 15, 29, 57, 85, 113, 141, and 169

  9. Absolute CD20 B-cell Count at Baseline

    Baseline absolute CD20 count is measured as the average between screening and predose on Day 1.

    Time frame: Baseline (Days -28 to -1)

  10. Time to 90 Percent (%) CD20 B-cell Depletion

    Time in days of first observation where CD20 counts fall to or below 10 percent (%) of baseline.

    Time frame: Baseline (Days -28 to -1) to long-term follow-up (LTFU) (Up to 18 months after EDV or 24 Week treatment period)

  11. Duration of Suppression Greater Than or Equal to 90 % of CD20 B-cell Count

    Time in days of last observation where CD20 counts remain at or below 10% of baseline. Participants whose samples are available were analyzed for this outcome measure.

    Time frame: Baseline (Days -28 to -1) to LTFU (Up to 18 months after EDV or 24 Week treatment period)

  12. Maximum Change From Baseline in Absolute CD20 of Peripheral Blood B-cell Count to LTFU

    The maximum degree of depletion (intensity) measured during the course of the study for each participant by subtracting 100 from the lowest observed percent of baseline value.

    Time frame: Baseline (Days -28 to -1) to LTFU (Up to 18 months after EDV or 24 Week treatment period)

  13. Number of Participants Positive for Anti-Drug Antibodies to MEDI-551

    A participant was considered anti-drug antibody positive across the study if they had a positive reading at any time point during the study.

    Time frame: Days 1, 29, 85 and 169

07

Results

Posted Oct 29, 2018

Participant flow

This study was conducted from 30 Jul 2012 to 20 Jun 2016 in United States, Poland, Spain, and Ukraine.

Participant flow — Overall Study
MilestonePLACEBO-IV-SCMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Started753436
Completed731436
Not completed022000
Withdrew: Withdrawal by subject011000
Withdrew: Death010000
Withdrew: Physician decision001000

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A TEAE were the events between administration of study drug (Day 1) and Day 169 that were absent before treatment or that worsened relative to pre-treatment state. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0

Time frame:
From study drug administration (Day 1) through the end of treatment period (Day 169)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPLACEBO-IV-SCMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)653336
PrimaryNumber of Participants With Treatment-emergent Serious Adverse Events (TESAEs)

A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect in the offspring of a participant who received the study drug. The TESAEs were the events between administration of study drug (Day 1) and long term follow up period (up to 18 months after early discontinuation visit or 24-week treatment period) that were absent before treatment or that worsened relative to pre-treatment state. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0

Time frame:
From study drug administration (Day 1) through the long term follow up period (up to 18 months after early discontinuation visit or 24 week treatment period).
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsPLACEBO-IV-SCMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)110011
PrimaryNumber of Participants With Clinical Laboratory Abnormalities Reported as TEAEs

Any clinically significant change in laboratory evaluations were recorded as AEs. The following parameters were analyzed for laboratory evaluations: haematology, serum chemistry, and urinalysis. Number of participants with TEAEs related to laboratory evaluations were reported.

Time frame:
From study drug administration (Day 1) through the end of treatment period (Day 169)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs
ParticipantsPLACEBO-IV-SCMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Hematology- Anaemia100000
Hematology- White blood cell count decreased000100
Serum chemistry- Liver function test increased010000
Serum chemistry- Hyponatraemia000001
PrimaryNumber of Participants With Vital Sign Abnormalities Reported as TEAEs

Vital sign parameters included blood pressure, temperature, pulse rate, and respiratory rate. The number of participants with TEAEs related to vital signs in participants were reported.

Time frame:
From study drug administration (Day 1) through the end of treatment period (Day 169)
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Abnormalities Reported as TEAEs
ParticipantsPLACEBO-IV-SCMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Blood pressure increased101002
Blood pressure decreased001000
Tachycardia001000
SecondaryTime to Reach Maximum Observed Serum Concentration (Tmax) of MEDI-551

The time to reach the maximum observed serum concentration of MEDI-551.

Time frame:
Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169
Reported as:
Median · Day
Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI-551
DayMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI-5510.14 (0.11 to 0.19)2.98 (2.87 to 6.97)0.07 (0.01 to 0.11)7.92 (7.82 to 8.02)0.12 (0.11 to 0.18)
SecondaryMaximum Observed Serum Concentration (Cmax) of MEDI-551

The maximum observed serum concentration (Cmax) of MEDI-551.

Time frame:
Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169
Reported as:
Mean · microgram per milliliter (mcg/mL)
Maximum Observed Serum Concentration (Cmax) of MEDI-551
microgram per milliliter (mcg/mL)MEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Maximum Observed Serum Concentration (Cmax) of MEDI-55117.9 ± 13.26.67 ± 2.8843.1 ± 11.424.7 ± 9.37248 ± 66.8
SecondaryArea Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC 0-last) of MEDI-551

The area under the concentration time curve from time 0 (dosing time) to the last measurable concentration (AUC 0-last) of MEDI-551.

Time frame:
Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169
Reported as:
Mean · microgram*day per milliliter(mcg*day/mL)
Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC 0-last) of MEDI-551
microgram*day per milliliter(mcg*day/mL)MEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC 0-last) of MEDI-551436 ± NA197 ± 92.61140 ± 278788 ± 4556850 ± 1340
SecondaryArea Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity) of MEDI-551

The area under the concentration-time curve from dosing extrapolated to infinity (AUC 0-infinity) of MEDI-551.

Time frame:
Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169
Reported as:
Mean · mcg*day/mL
Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity) of MEDI-551
mcg*day/mLMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity) of MEDI-551440 ± NA201 ± 91.51150 ± 286794 ± 4536950 ± 1430
SecondaryDose Normalized Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity/D) of MEDI-551

The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity post dose normalized by MEDI-551.

Time frame:
Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169
Reported as:
Mean · mcg*day/mL/mg
Dose Normalized Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity/D) of MEDI-551
mcg*day/mL/mgMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Dose Normalized Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity/D) of MEDI-5517.34 ± NA3.35 ± 1.525.75 ± 1.432.65 ± 1.515.79 ± 1.19
SecondaryClearance of MEDI-551

Systemic clearance (CL) for MEDI-551 IV cohorts and apparent clearance (CL/F) for MEDI-551 SC cohorts were calculated

Time frame:
Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169
Reported as:
Mean · mL/day
Clearance of MEDI-551
mL/dayMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Clearance of MEDI-551139 ± NA351 ± 177181 ± 44.5457 ± 214180 ± 41.5
SecondaryTerminal Elimination Half-life (t1/2) of MEDI-551

The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI-551.

Time frame:
Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169
Reported as:
Mean · Day
Terminal Elimination Half-life (t1/2) of MEDI-551
DayMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Terminal Elimination Half-life (t1/2) of MEDI-55117.7 ± NA12.3 ± 1.7117.7 ± 6.2715.1 ± 4.3118.7 ± 2.03
SecondaryAbsolute Subcutaneous Bioavailability (F%) of MEDI-551

Bioavailability (F%) is the fraction of the study drug absorbed through non-intravenous administration compared with the corresponding intravenous administration of the same drug.

Time frame:
Predose (Day 1) and Days 4, 8, 15, 29, 57, 85, 113, 141, and 169
Reported as:
Number · Percentage of bioavailability
Absolute Subcutaneous Bioavailability (F%) of MEDI-551
Percentage of bioavailabilityMEDI-551 60 Mg-SCMEDI-551 300 Mg-SC
Absolute Subcutaneous Bioavailability (F%) of MEDI-5515846
SecondaryAbsolute CD20 B-cell Count at Baseline

Baseline absolute CD20 count is measured as the average between screening and predose on Day 1.

Time frame:
Baseline (Days -28 to -1)
Reported as:
Mean · cells/mcL
Absolute CD20 B-cell Count at Baseline
cells/mcLPLACEBO-IV-SCMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Absolute CD20 B-cell Count at Baseline190 ± 99.1173 ± 36.1180 ± 108183 ± 65.5366 ± 257201 ± 91.3
SecondaryTime to 90 Percent (%) CD20 B-cell Depletion

Time in days of first observation where CD20 counts fall to or below 10 percent (%) of baseline.

Time frame:
Baseline (Days -28 to -1) to long-term follow-up (LTFU) (Up to 18 months after EDV or 24 Week treatment period)
Reported as:
Median · Day
Time to 90 Percent (%) CD20 B-cell Depletion
DayPLACEBO-IV-SCMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Time to 90 Percent (%) CD20 B-cell Depletion—15.0 ± 1.1088.0 ± 50.325.0 ± 6.1915.0 ± 4.0414.5 ± 5.65
SecondaryDuration of Suppression Greater Than or Equal to 90 % of CD20 B-cell Count

Time in days of last observation where CD20 counts remain at or below 10% of baseline. Participants whose samples are available were analyzed for this outcome measure.

Time frame:
Baseline (Days -28 to -1) to LTFU (Up to 18 months after EDV or 24 Week treatment period)
Reported as:
Median · Day
Duration of Suppression Greater Than or Equal to 90 % of CD20 B-cell Count
DayPLACEBO-IV-SCMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Duration of Suppression Greater Than or Equal to 90 % of CD20 B-cell Count—149 ± 62.8100 ± 28.3180 ± 39.2211 ± 17.3254 ± 45.3
SecondaryMaximum Change From Baseline in Absolute CD20 of Peripheral Blood B-cell Count to LTFU

The maximum degree of depletion (intensity) measured during the course of the study for each participant by subtracting 100 from the lowest observed percent of baseline value.

Time frame:
Baseline (Days -28 to -1) to LTFU (Up to 18 months after EDV or 24 Week treatment period)
Reported as:
Mean · Percentage of cells
Maximum Change From Baseline in Absolute CD20 of Peripheral Blood B-cell Count to LTFU
Percentage of cellsPLACEBO-IV-SCMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Maximum Change From Baseline in Absolute CD20 of Peripheral Blood B-cell Count to LTFU25.0 ± 31.299.8 ± 0.077099.2 ± 0.78799.7 ± 0.22599.8 ± 0.18299.8 ± 0.237
SecondaryNumber of Participants Positive for Anti-Drug Antibodies to MEDI-551

A participant was considered anti-drug antibody positive across the study if they had a positive reading at any time point during the study.

Time frame:
Days 1, 29, 85 and 169
Reported as:
Count of participants · Participants
Number of Participants Positive for Anti-Drug Antibodies to MEDI-551
ParticipantsPLACEBO-IV-SCMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IV
Day 1 (Baseline)000000
Day 29000000
Day 85000000
Day 169000000

Adverse events

Collected over AEs were collected from the time of signature on informed consent through Day 169, SAEs were collected upto the long-term follow-up period (up to 18 months after early discontinuation visit or 24-week treatment period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PLACEBO-IV-SC—1/7 (14.3%)5/7 (71.4%)
MEDI-551 60 Mg-SC—0/3 (0%)3/3 (100%)
MEDI-551 100 Mg-IV—0/4 (0%)3/4 (75%)
MEDI-551 300 Mg-SC—1/3 (33.3%)2/3 (66.7%)
MEDI-551 30 Mg-IV—1/5 (20%)4/5 (80%)
MEDI-551 600 Mg-IV—1/6 (16.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventPLACEBO-IV-SCMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 30 Mg-IVMEDI-551 600 Mg-IV
PyrexiaGeneral disorders0/70/30/41/30/50/6
Accidental overdoseInjury, poisoning and procedural complications0/70/30/40/31/50/6
Urinary tract infectionInfections and infestations0/70/30/40/30/51/6
Multiple sclerosis relapseNervous system disorders1/70/30/40/30/50/6
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPLACEBO-IV-SCMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 30 Mg-IVMEDI-551 600 Mg-IV
NasopharyngitisInfections and infestations0/70/32/41/31/51/6
Oral herpesInfections and infestations1/70/32/40/30/50/6
Upper respiratory tract infectionInfections and infestations0/71/32/40/31/50/6
Infusion related reactionInjury, poisoning and procedural complications2/70/31/40/32/53/6
AstheniaGeneral disorders0/70/31/41/30/50/6
PyrexiaGeneral disorders0/71/31/40/30/50/6
Urinary tract infectionInfections and infestations0/71/30/41/30/51/6
Blood pressure increasedInvestigations1/71/30/40/30/52/6
Back painMusculoskeletal and connective tissue disorders1/70/31/41/30/50/6
HeadacheNervous system disorders1/70/30/41/30/51/6

Baseline characteristics

Safety Population is defined as all participants who received any amount of study drug. One participant in the 30 mg IV dose cohort received an incorrect dose of study drug due to kits not administered according to the IVRS; the participant received MEDI-551 100 mg IV instead of 30 mg on Day 1.

Age, Continuous
Age, Continuous(Years)PLACEBO-IV-SCMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IVTotal
Mean43.0 ± 15.942.4 ± 7.846.7 ± 16.346.5 ± 13.856.0 ± 6.144.2 ± 10.145.4 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)PLACEBO-IV-SCMEDI-551 30 Mg-IVMEDI-551 60 Mg-SCMEDI-551 100 Mg-IVMEDI-551 300 Mg-SCMEDI-551 600 Mg-IVTotal
Female63232319
Male1211139
08

Study locations

16 sites
  • Research Site
    Scottsdale, Arizona, United States
  • Research Site
    Long Beach, California, United States
  • Research Site
    Sacramento, California, United States
  • Research Site
    Denver, Colorado, United States
  • Research Site
    Tampa, Florida, United States
  • Research Site
    Marlton, New Jersey, United States
  • Research Site
    Winston-Salem, North Carolina, United States
  • Research Site
    Cordova, Tennessee, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Katowice, Poland
  • Research Site
    Szczecin, Poland
  • Research Site
    Barcelona, Spain
  • Research Site
    Girona, Spain
  • Research Site
    Sevilla, Spain
  • Research Site
    Donetsk, Ukraine
  • Research Site
    Kyiv, Ukraine
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2012 to primary completion in Jan 2015, 32 months.

Results were first posted in Oct 2018, 3 years 9 months after primary completion.

Of 39 industry-sponsored phase 1 interventional studies under Multiple Sclerosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's 32 months is above that.

Counting every sponsor, half of 92 studies reached it within 30 months; a quarter within 9 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2012
First posted
Apr 26, 2012
StartActual
Apr 24, 2012
Primary completionActual
Jan 2, 2015
CompletionActual
Jun 20, 2016
Results first posted
Oct 29, 2018
Last update
Oct 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01585766
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Apr 26, 2012
Start date
Apr 24, 2012
Primary completion
Jan 2, 2015
Completion
Jun 20, 2016
Results posted
Oct 29, 2018
Last update
Oct 29, 2018

Study contacts

Armando Flor
study director · MedImmune LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion